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Both prolactin (PRL) and estrogen (E2) are involved in the pathogenesis and 
progression of mammary neoplasia, but the mechanisms by which these hormones 
interact to exert their effects in breast cancer cells is not well understood. We show 
here that PRL is able to activate the unliganded estrogen receptor (ER). In breast 
cancer cells PRL activates a reporter plasmid containing estrogen response 
elements (EREs) and induces the ER target gene pS2. These actions are blocked by 
the antagonist ICI 182,780, showing that ER is required for the PRL-mediated 
effect. Moreover, PRL leads to phosphorylation of ER in serine-118 (P-ER), a 
modification related to the potentiation of ligand-independent transcriptional 
activation. Additionally, PRL mimics the effect of E2 on target gene expression by 
inducing cyclical recruitment of ER and P-ER to ERE-containing promoters, 
resulting in recruitment of coactivators and acetylation of histone H3. Finally, PRL 
induces expression of c-Myc and Cyclin D1 and leads to increased cell 
proliferation, which is specifically antagonized by ICI 182,780 or ER depletion. 
These results demonstrate that ligand-independent ER activation appears to be 
an important component of the proliferative and transcriptional actions of PRL in 
breast cancer cells. 
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Introduction 
PRL plays a key role in mammary gland development and PRL involvement in breast 
cancer has now been clearly established. Both the hormone and its receptor are 
expressed in mammary tumours and in breast cancer cell lines, thereby creating 
autocrine/paracrine modes of action for PRL (Clevenger et al., 1995; Ginsburg and 
Vonderhaar, 1995; Touraine et al., 1998; Schroeder et al., 2002). Different studies have 
correlated prolactin levels with breast cancer incidence, showing that prolactin receptor 
(PRLR) levels are generally higher in breast tumours than in normal mammary tissue 
(Clevenger et al., 2003; Tworoger and Hankinson, 2006). Furthermore, disruption of 
PRL signalling in breast cancer cells causes cell growth inhibition apoptosis induction 
(Fuh and Wells, 1995).  
Different signalling pathways that are activated upon PRL binding to its receptor 
have been demonstrated to lead to breast cancer cell proliferation. In breast cancer cell 
lines PRL stimulates both the JAK1 and JAK2 pathways (Campbell et al., 1994; Liu et 
al., 1997; Neilson et al., 2007), and we have previously demonstrated that PRL 
stimulates Src kinases, which then independently activate Fak/ERK1/2 and the PI3K-
dependent p70S6K and Akt kinases (Acosta et al., 2003). Activated ERK1/2 and AKT 
lead among others to increased AP-1 complexes, and induces the expression of cell 
cycle progression genes such as cyclin D1 or c-myc (Acosta et al., 2003; Brockman et 
al., 2002; Gutzman et al., 2005).  
Estrogen also plays a key role in normal breast development, as well as in 
growth and progression of breast cancer. The biological actions of estrogens are 
mediated by binding to nuclear estrogen receptors (ER and ER). In breast cancer 
cells expressing, ERs estradiol (E2) has potent proliferative effects and treatment with 
ER antagonists is the current hormone therapy of choice for the treatment of ER-
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positive breast cancers (Yager and Davidson, 2006). A key event for the anti-
proliferative effects of anti-estrogens appears to be the down-regulation of Cyclin D1 
and c-Myc (Carroll et al., 2002; Musgrove et al., 1993). 
Normally, ERs act as ligand dependent transcription factors by binding as 
homodimers to estrogen response elements (EREs) in target genes (Aranda and Pascual, 
2001). However, there is increasing evidence that the presence of estrogen is not an 
absolute requirement for receptor activation, since growth factors, such as IGF-1 or 
EGF, and intracellular protein kinases can induce an estrogen-independent ER 
activation in different model systems (Butt et al., 2005). In breast cancer cells 
phosphorylation of the Ser-118 residue in the human ER A/B domain by growth 
factors stimulated mitogen-activated protein kinase (MAPK) (Bunone et al., 1996; Chen 
et al., 2000; Kato et al., 1995; Medunjanin et al., 2005; Park et al., 2005; Weitsman et 
al., 2006), results in the potentiation of the ER ligand-independent transcriptional 
activation function (AF-1). Interestingly, it has been proposed that phosphorylation in 
Ser-118 may be associated with an increase in estrogen agonism, progression of breast 
cancer, resistance to tamoxifen therapy, and estrogen-independent growth of MCF-7 
cells (Likhite et al., 2006; Murphy et al., 2006). Recently it has been shown that the 
pure ER antagonist ICI 182,780 (ICI) can also induce ER phosphorylation in Sert-118 
(De los Santos et al., 2007; Lipfert et al., 2006).  
In the normal mammary gland PRL and estrogen act synergistically to favour 
mammary gland growth and development (Hennighausen and Robinson, 2005). ER 
and PRLR are coexpressed in many breast tumours (Murphy et al., 1984; Ormandy et 
al., 1997). However, the mechanisms by which these hormones interact to affect breast 
cancer cell functions is not completely understood. One of the mechanisms of PRL and 
estrogen interaction is the cross-regulation of their receptors (Dong et al., 2006; 
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Ormandy et al., 1997). It has been described that PRL increases ER levels and E2 
responsiveness in breast cancer cells (Gutzman et al., 2004a; Shafie and Brooks, 1977). 
In addition, both PRL and E2 increase ERK1/2 phosphorylation and cooperatively 
activate the transcription factor AP-1 (Gutzman et al., 2005; Gutzman et al., 2004b). 
However, the possibility that PRL could also mediate some of its actions by inducing 
estrogen-independent ER activation has not been yet explored. 
In this study we show that PRL increases ER activity in an estrogen-independent 
manner in T47D and MCF-7 cells. We found that PRL induces Ser118-ER 
phosphorylation, increases the activity of an ERE-containing reporter plasmid, up-
regulates the expression of the ER-dependent gene pS2, and induces the recruitment of 
ER and coactivators to ER target promoters. Moreover, ICI abolishes the effect of 
PRL on ERE stimulation and pS2 gene expression and blocks PRL-dependent 
proliferation, demonstrating that ligand-independent ER activation by PRL is an 
important mediator of the mitogenic and transcriptional effects of this hormone in breast 
cancer cells. 
 
Results 
 
PRL-dependent activation of unliganded ER 
To explore the interaction between PRL and ERs, we analyzed the effect of this 
hormone on the transcription of an estrogen responsive reporter plasmid. As shown in 
Figure 1A, treatment of T47D cells with PRL, in the absence of E2, caused a significant 
increase in luciferase activity at the different time points examined. In order to prove 
that the effect of PRL on the reporter plasmid was due to ER activation, cells were 
incubated either with PRL or with E2 for 6 and 40 h in the absence and presence of ICI. 
 6 
As shown in Figure 1B, the ER antagonist blocked not only the response to E2 but also 
to PRL.  
To determine the effect of PRL on endogenous ER-dependent gene expression, 
we analysed transcripts for the well-known estrogen target gene pS2, containing EREs 
in its regulatory region (Nunez et al., 1989). PRL significantly induced pS2 mRNA 
levels in T47D cells (Figure 2A), without increasing ER mRNA levels (Figure 2B). 
PRL-mediated transcription by was abolished when cells were treated with the ER 
antagonist, further demonstrating that the lactotrophic hormone can stimulate the 
unliganded ER. 
 
PRL induces Ser118-ER phosphorylation 
Post-translational modifications of ER are emerging as important regulatory elements 
of cross talk between different signalling pathways. In particular, phosphorylation at 
Ser-118, has been implicated in the ligand-dependent and -independent effects of ER 
and in tamoxifen resistance of breast tumours (Lonard et al., 2000; Murphy et al., 2004; 
Wijayaratne and McDonnell, 2001). Thus, we analyzed the effect of incubation with 
PRL on ER phosphorylation in Ser-118 (P-ER  by western blot. As shown in Figure 
-ER levels, 
whereas total ERlevels remained unchanged through the period in which increased 
phosphorylation was observed. Similar results were obtained in MCF-7 cells (Figure 
3B), demonstrating that the effect of PRL is not restricted to the T47D cell line. We also 
assessed the effect of ICI on PRL-induced ER phosphorylation (Figure 3C). Short-
term incubation with ICI increased the effect of PRL on P-ER levels, but reduced 
phosphorylation was observed after 6 h of incubation, due to the expected strong down-
regulation of ER expression caused by ICI (Lonard et al., 2000; Wijayaratne and 
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McDonnell, 2001). This reduction was not observed when PRL was combined with the 
ER antagonist tamoxifen that does not induce receptor down-regulation, and under these 
conditions a strong phosphorylation was found after 24 h of incubation in the presence 
of both compounds (Fig. 3D). Finally, induction of Ser-118 phosphorylation by PRL 
was blocked in the presence of the inhibitors PD184352, LY294002 and PP2 (Figure 
3E), showing that ERK and PI3K activation that we have previously shown to be 
secondary to c-Src stimulation (Acosta et al., 2003), are required to induce receptor 
modification. 
 
PRL induces ER recruitment to estrogen target genes 
Estrogen-dependent transcriptional activation has been shown to involve occupancy of 
the target promoter by ER (Metivier et al., 2003; Shang et al., 2000) and P-Ser118-ER 
is also recruited to the promoters of estrogen-regulated genes (Weitsman et al., 2006). 
To analyse whether treatment of breast cancer cells with PRL could also induce the 
recruitment of ER and P-Ser118-ER to the target promoter, we performed chromatin 
immunoprecipitation (ChIP) assays in -amanitin synchronized populations of cells to 
compare pS2 promoter occupancy by the receptor in T47D cells incubated with PRL or 
E2. As shown in Figure 4, E2 recruited ER to the pS2 promoter region containing the 
ERE and known to be required for E2 regulation of transcription (Nunez et al., 1989). 
This binding increased at 40 min and then decreased, in agreement with data obtained in 
other breast cancer cell line (MCF-7), where ER recruitment to the promoter is 
cyclical (Metivier et al., 2003; Shang et al., 2000). Interestingly, PRL induced ER 
binding to the pS2 promoter with similar kinetics. Moreover, we observed that the 
phosphorylated receptor was also recruited in response to both hormones. P-Ser118-
ER was essentially absent from the promoter in the untreated cells, but was already 
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associated after 20 min of incubation with either E2 or PRL, decreasing at 60 min and 
increasing again at 80 min. These changes were specific for the ERE-containing region 
because no estrogen receptor recruitment was observed when an irrelevant upstream 
region of the promoter was amplified. The effect of PRL applies to other ER target 
promoters, as demonstrated by a significant recruitment of ER and P-Ser118-ER to 
the ERE-containing GREB1C promoter (Bourdeau et al., 2004) in response to PRL. In 
addition, PRL as well as E2 caused pS2 promoter occupancy by ER and P-Ser118-
ER in MCF-7 cells (see Supplementary Fig.1), showing that this finding can be 
extended to other breast cancer cell lines.   
 Nuclear receptors stimulate transcription by recruitment of coactivators that lead 
to local alteration of chromatin structure generated by posttranslational modifications of 
histones such as acetylation (Aranda and Pascual, 2001). Therefore, we examined by 
ChIP the effect of PRL on the binding of the p160 coactivator SRC-1 and acetylated 
histone H3 to the pS2 promoter. As illustrated in Figure 5, PRL- and E2-induced ER 
binding correlated with the recruitment of the coactivator and increased promoter 
acetylation. These data are consistent with the occupancy of estrogen-regulated 
promoters by ER and P-Ser118-ER in response to PRL treatment, strongly 
suggesting that ligand-independent receptor recruitment may represent a mechanism for 
transcriptional regulation of ER-target genes by PRL. 
 
ICI blocks PRL-dependent breast cancer cell proliferation  
Previous studies have demonstrated that PRL induces moderate T47D cell growth 
(Acosta et al., 2003). The ability of ICI to antagonize the effect of PRL on transcription 
suggested that this compound could also suppress PRL-dependent cell proliferation. As 
shown in Figure 6A, incubation of T47D cells with PRL induced an increase of 
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[
3
H]thymidine incorporation. The moderate activation of cell proliferation above basal 
levels induced by PRL may be due to the fact that these cells produce PRL which by an 
autocrine/paracrine feedback loop allow can affect breast cancer cells even under 
serum-free media conditions (Clevenger et al., 1995; Reynolds et al., 1997; Schroeder 
et al., 2002). In addition, ICI (from nanomolar to millimolar concentrations) caused a 
marked reduction of [
3
H]thymidine uptake and abolished the mitogenic effect of PRL. 
ICI also blocked the increase in T47D cell number triggered not only but E2 but also by 
PRL (Figure 6B). To further examine the effect of PRL and ICI on breast cancer cell 
proliferation, flow cytometry analysis was performed in T47D and MCF-7 cells. Most 
cells were in G0/G1 as corresponding with serum starvation, but PRL treatment caused 
a modest but consistent reduction in the number of cells in this phase of the cell cycle 
and induced a concomitant increase in the percentage of cells in S-phase. Significantly, 
incubation with ICI abolished the effect of PRL in both T47D cells (Figure 6C) and 
MCF-7 cells (Supplementary Figure 2). These results suggest again that ER activity is 
required for the proliferative response of breast cancer cells to the lactotropic hormone. 
To prove this point, ER was knocked-down by means of siRNA in T47D cells (Figure 
6D), and the effect of PRL on the cell cycle analysed by flow cytometry (Figure 6E). 
Stimulation of cell cycle progression by PRL was abolished in ER-depleted cells, 
indicating that this receptor is required for PRL-induced proliferation. As expected, the 
mitogenic effect of E2 was also abolished in cells transfected with siER. 
PRL-induced proliferation of breast cancer cells appears to require ERK1/2 and 
AKT activation. Therefore, it was possible that ICI could inhibit the effect of the 
polypeptide hormone on proliferation by blocking activation of these kinases. However, 
incubation with PRL for different time periods was equally effective in stimulating 
ERK1/2 and PI3K activity in the presence and absence of ICI in T47D cells (Figure 7A) 
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and in MCF-7 cells (Supplementary Figure 3A). In addition, lowering ER by means of 
siRNA did not block phosphorylation (Figure 6C). 
PRL-stimulated mitogenic signalling cascades ultimately induce the expression 
of c-Myc and Cyclin D1 (Acosta et al., 2003), which are critical molecules for G1/S cell 
cycle progression. We therefore evaluated whether ICI could block the effect of PRL on 
expression of these proteins. As illustrated in Figure 7C, and in agreement with its 
effect  on proliferation, PRL induced a weak but detectable increase of these proteins in 
T47D cells. At short incubation times ICI was unable to repress c-Myc or Cyclin D1 
levels. However, at incubations longer than 6 h, and concomitant with ER depletion, 
ICI caused a marked reduction of these proteins, reversing PRL induction and lowering 
expression to levels below those of untreated T47D cells. Similar results were obtained 
in MCF-7 cells in which ICI also caused a time-dependent reduction of Cyclin D1 
expression (Supplementary Figure 3B). 
Recently, it has been reported that Cyclin D1 induction by E2 involves 
ERrecruitment to an enhancer located downstream from the coding region (Eeckhoute 
et al., 2006). We therefore analysed by ChIP binding of ER and P-Ser118-ERto this 
enhancer (enh 2), as well as to an upstream promoter region (enh 1) also shown to bind 
ER (Eeckhoute et al., 2006). Incubation not only with E2, but also with PRL caused 
association of total and phosphorylated ER with these regions both in T47D (Figure 
8A) and MCF7 cells (Figure 8B), thus providing a link between PRL and breast cancer 
cell proliferation.   
 
Discussion 
 
ER normally acts as a transcription factor in response to binding of its cognate ligand. 
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However, there is increasing evidence that the presence of estrogen is not an absolute 
requirement for activation of this receptor, since growth factors such as IGF-1 or EGF 
and intracellular protein kinases can induce an ER activation independently of ligand 
binding (Butt et al., 2005). In this work we show that PRL can also activate ER in 
breast cancer cells leading estrogen-independent induction of ER target gene 
expression. We have demonstrated that PRL increases ERE activity in transient 
transfection assays and also induces transcription of the endogenous ER target gene 
pS2, considered a marker of breast cancer progression and as a resistance predictor of 
breast tumours to ER antagonists (Johnston et al., 1995). These actions are observed in 
serum free medium lacking phenol red and therefore most likely represent ligand-
independent receptor activation, but we cannot discard the possibility that PRL could 
synergize with residual levels of estrogen. The effects of PRL are abolished by the pure 
antagonist ICI, demonstrating the involvement of ER activation. Moreover, we show 
that PRL mimics the effect of E2 promoting the recruitment of ER to endogenous 
target promoters, independently of E2. PRL-induced binding of ER to the promoter 
determines coactivator recruitment and histone acetylation, both landmarks of receptor-
mediated transcriptional activation. 
Increased ER levels are common in breast cancer (Fabris et al., 1987) and have 
been associated with aberrant promoter occupancy, increased gene expression and cell 
proliferation in the absence of hormonal stimulation (Fowler et al., 2004). Since it has 
been reported that PRL increases ER levels in breast cancer cells (Gutzman et al., 
2004a; Shafie and Brooks, 1977), the stimulatory effect of PRL on the ER target genes 
could be due to ER induction. However, we did not observe increased receptor 
expression over the period in which PRL stimulates ER-dependent gene transcription. 
It has been proposed that phosphorylation in the AF-1 domain is associated with 
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estrogen-independent ER activation. Ser-118 is a well-studied phosphorylation site in 
ER and both ER ligands and growth factors can induce this modification (Bunone et 
al., 1996; Chen et al., 2000; Chen et al., 2002; Kato et al., 1995). Our results show that 
PRL signalling pathways cause a rapid and sustained Ser-118-ER phosphorylation. 
Chemical inhibition of Src, ERK or AKT abolish receptor phosphorylation by PRL. 
This is surprising because the inhibitors used are accepted to be specific and a partial 
reduction would have been predicted if multiple pathways are involved in 
phosphorylation. Interestingly, we have reported that each of these inhibitors also block 
PRL-induced breast cancer cell proliferation (Acosta et al., 2003) and these pathways 
are also required for the mitogenic effects of estrogen (Migliaccio et al., 1996; 1998). 
 Our results also show that PRL causes recruitment of the phosphorylated receptor to 
target promoters. Therefore, increased receptor modification could also contribute to the 
activation of ER-dependent gene transcription secondary to PRL treatment in breast 
cancer cells. However, it should be noted that this modification cannot be univocally 
linked to transcriptional activation, since ER antagonists also cause Ser-118-ER 
phosphorylation (Lipfert et al., 2006). In fact, we have previously shown that ICI is at 
least as strong as E2 to induce a sustained increase of Ser-118 ER phosphorylation in 
MCF-7 cells (De los Santos et al., 2007), and in this work we observe that ER 
antagonists cooperate with PRL to increase P-Ser118-ER levels. In addition to ER 
phosphorylation, the activation of ERK1/2 and AKT by PRL may also lead to 
phosphorylation of receptor coregulators (coactivators and corepressors). This 
modification alters their activity, their interaction with transcription factors and their 
cellular redistribution (Jonas and Privalsky, 2004; Wu et al., 2005) and could therefore 
contribute to PRL-dependent transcriptional stimulation. Furthermore, it has been 
demonstrated that induction of progesterone target genes in breast cancer cells involves 
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activation of the ERK1/2 cascade and phosphorylation of histone H3, as a pre-requisite 
for recruitment of coactivators and transcriptional activation (Vicent et al., 2006). It is 
plausible that activation of this signalling pathway by PRL could also induce histone H3 
phosphorylation, promoting the transcription of ER target genes.  
Both E2 and PRL induce breast cancer cell growth by modifying the expression of 
key regulatory components of cell-cycle progression such as Cyclin D1 or c-Myc 
(Acosta et al., 2003; Carroll et al., 2002; Musgrove et al., 1993; Musgrove et al., 1994; 
Schroeder et al., 2002). These proteins are frequently over-expressed in human breast 
cancers and have been implicated in the development of mammary hyperplasia
 
and 
carcinogenesis (McNeil et al., 2006; Wang et al., 2007). We have confirmed that PRL 
induces moderate
 
Cyclin D1 and c-Myc expression, and that the anti-estrogen 
counteracts their induction, as well as PRL-dependent breast cancer cell growth. The 
finding that induction of these proteins by PRL is modest has been attributed to the 
production of PRL within the mammary cells themselves, since in MCF-7 cells that do 
not express endogenous PRL treatment with the hormone has stronger effects on the 
levels of cell cycle regulators and on cell proliferation (Schroeder et al., 2002).  
The fact that repression of cell cycle proteins by ICI is concomitant with ER down-
regulation reinforces the idea that ER activation is involved in the effect of the 
lactotrophic hormone on breast cancer cell proliferation. There was the possibility that 
the ability of ICI to repress cell proliferation in the presence of PRL could simply 
indicate that the ER antagonist targets processes essential for cell cycle progression 
rather than inhibiting processes activated by PRL. However, we found that depletion of 
ER with siRNA was able to block the mitogenic effect of PRL, demonstrating a key 
role for ERin this hormonal action. In contrast, other PRL actions such as ERK 
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activation appear to be ERindependent, since they are not blocked by treatment with 
ICI or by ERdown-regulation. 
 In summary, our results indicate a novel layer of complexity in the interaction 
between ER and PRL signalling in breast cancer. The finding that the polypeptide 
hormone can activate ER in a ligand-independent manner evidences the significance 
of this mechanism in the development of breast cancer and suggests that anti-estrogen 
therapy acts not only by inhibiting E2 actions, but also by antagonizing PRL effects on 
breast cancer cells.  
 
Materials and Methods 
 
Materials. Ovine PRL (NIDDK-oPRL-20, 31 IU/mg) was kindly provided by the 
National Hormone and Pituitary Program of the National Institute of Diabetes and 
Digestive and Kidney Diseases (Bethesda, MD). ICI 182,780 was obtained fron Tocris 
Cookson (Ballwin, MO) and estradiol (E2) and tamoxifen (TMX) from Sigma (San 
Luis, MO). PD184352, LY29402 and PP2 were obtained from Calbiochem (San Diego, 
CA). [
3
H] thymidine was obtained from Amersham Pharmacia Biotech 
(Buckinghamshire, UK). 
 
Cell Culture and Transfection. T47D cells were grown in DMEM supplemented with 
10% fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin, and 72 h before transfection were shifted to serum free medium lacking 
phenol red. Cells were transiently transfected with 5 µg of a luciferase reporter plasmid 
that contains three copies of a consensus ERE by incubation with a mixture of cationic 
liposomes (1.5 µl/µg DNA) for 6 h (De los Santos et al., 2007). Cells were then treated 
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with 100 nM PRL, ICI or E2 for the indicated times, and luciferase activity determined. 
Experiments were performed with triplicate cultures and each experiment was repeated 
at least 3 times. Data are represented as means ± standard deviations. Short-interfering 
RNA for ER and Non-target control were purchased from Dharmacon (Cat. L-003401-
00 and D-001210-01-05). siRNA transfections were performed using 33 nM of each 
siRNA and lipofectamine
TM
2000 (Invitrogen), as recommended by the manufacturer. 
The efficiency of knock-down was determined by Western Blot. 
 
Cell proliferation. Exponentially growing T47D cells were inoculated in 24-well plates, 
and 24 h later were washed and shifted to serum- and phenol-free medium. Cells were 
kept in this medium for 48 h and then treated for 72 h with PRL and/or ICI, and for the 
last 4 h with 0.5 µCi/well of [
3
H]thymidine (48 Ci/mmol). Cells were disrupted and 
incorporated radioactivity was determined in a liquid scintillation Beta Wallac Counter. 
Alternatively, cells were inoculated in 60 mm Petri dishes and the number of cells 
counted in Neubauer chambers after treatment with PRL or E2 alone or in combination 
with ICI. 
 
Flow cytometry. Duplicate cultures of T47D and MCF-7 cells grown in 60 mm Petri 
dishes were transferred to the serum and phenol red-depleted medium and after 72 h 
incubated with PRL and/or ICI for different time periods. Cells were collected and 
stained with propidium iodide for sorting as previously described (De los Santos et al., 
2007).  
 
Western blot. Cells previously incubated for 48 h in serum- and phenol red-depleted 
medium were treated with PRL (100 ng/ml) alone or in combination with ICI or 
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tamoxifen (100 nM) for the times indicated. Antagonists were added 2h prior to PRL. 
Cells were washed twice in ice-cold Tris-buffered saline (TBS: 20 mM Tris-HCl, pH 
7.6; 140 mM NaCl) with 0.1 mM Na3VO4 and lysed at 4°C in 1 ml of lysis buffer (10 
mM Tris-HCl, pH 7.6; 50 mM NaCl; 30 mM sodium pyrophosphate; 5 mM EDTA; 
0.5% Nonidet P-40; 1% Triton X-100; 50 mM NaF; 0.1 mM Na3VO4; 1 mM 
phenylmethylsulfonylfluoride; 1 mM benzamidine; 1 mM iodoacetamide; 1 mM 
phenantroline). Cell lysates were obtained by centrifugation at 17,000 x g for 15 min at 
4°C, protein concentration in the supernatant was determined by the BCA protein assay 
(Pierce Chemical Co., Rockford, IL), and lysates were adjusted to equivalent 
concentrations with lysis buffer. Proteins from cell lysates were separated in SDS-
PAGE and transferred to PDVF membranes (Immobilon Millipore) that were blocked 
for 1 h at room temperature with 4% BSA. Incubation with antibodies was performed in 
blocking solution for 1 h at room temperature. Blots were visualized with ECL 
(Amersham). Rabbit polyclonal antibodies to Erk2 (C14), Akt (H-136), c-Myc (9E10) 
and Cyclin D1 (H-295) were obtained from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA). The ERantibodies used were either from Dako (1D5) or a kind gift of S. 
Ramos. The later antibody detects a doublet where the upper band is the non-specific. 
Antiphospho antibodies to pErk1/2, pAkt and pSer118-ER were from New England 
Biolabs (Beverly, MA). Secondary horseradish peroxidase-conjugated antibodies were 
purchased from Biosource International (Camarillo, CA), and the enhanced 
chemiluminescence (ECL) kit was from Amersham Pharmacia Biotech 
(Buckinghamshire, UK). Primary antibodies were used at a 1:1000 dilution.  
 
Real-time PCR. Cells were cultured for 48 h in depleted medium prior to incubation with 
PRL and/or ICI. Total RNA was extracted using Tri Reagent (Sigma) and mRNA levels 
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were analyzed by quantitative real time PCR (Q-RT-PCR). RT was performed with 2 µg 
of RNA following specifications of SuperScript
TM
 First-Strand Synthesis System 
(Invitrogen Life Technologies). PCRs reactions were performed in a Mx3005P 
thermocycler (Stratagene) and detected with Sybr Green using the following primers: 
pS2 5´-TCCCCTGGTGCTTCTATCCTAA-3´ (forward) and 5´-
AGTGTCTAAAATTCACACTCCTCTTCT-3´ (reverse), and ER 5´-
CCACCAACCAGTGCACCATT-3' (forward) and 5´-
GGTCTTTTCGTATCCCACCTTTC-3´ (reverse). Values obtained were corrected by 
GAPDH expression determined with primers 5´-ACAGTCCATGCCATCACTGCC-3´ 
(forward) and 5´-CTAGCTGACCTCCTTGACCTG -3´ (reverse). Results were analyzed 
by the CT comparative method (∆∆CT).  
 
ChIP assays. Cells growing in p150 dishes were maintained in depleted medium for 72 
hours, washed twice in serum-free medium and treated for 2.5 hours with 2.5 µM -
amanitin (Sigma). As previously described this treatment is required for a preliminary 
silencing of the pS2 promoter (Metivier et al., 2003). Cells were then washed and 
treated with PRL or E2. At the indicated time points, cells were fixed with 1% 
formaldehyde for 15 min at 37 ºC. The Chromatin Immunoprecipitation Assay kit from 
Upstate (Cat. 17-295) was used. Sonication was performed using a Bioruptor UCD-
200TM (Diagenode) following manufacturer’s directions. For each 
immunoprecipitation 2.5-3.0x10
6
 cells and 3 µg of the following antibodies: anti-
acetylated histone 3 (06-599, Upstate), anti-SRC-1 (sc-8995), anti-ER (sc-542), anti-
pSer118-ER (sc-12915-R), and normal rabbit serum immunoglobulins (sc-2027). 
DNAs were subjected to 35 cycles of PCR with primers: forward 5´-
GCCATCTCTCACTATGAATC-3´ and reverse 5´-GGATTTGCTGATAGACAGAG-
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3´ to amplify the ERE-containing pS2 promoter region (-392/-199 bp); forward 5´-
CAGTCTGGCAAATCATTCCCAAAC-3´ and reverse 5´-
CACATCTGAGAGGTAAGAGGAGGTG-3´ to amplify an irrelevant pS2 region 
(Weitsman et al., 2006); forward 5´-TTGTTGTAGCTCTGGGAGCA-3´ and reverse 
5´-CAACCAGCCAAGAGGCTAAG-3´ to amplify the proximal GREB1C promoter 
region that contains the ERE; forward 5´-CAGTTTGTCTTCCCGGGTTA-3´ and 
reverse 5´-TCATCCAGAGCAAACAGCAG-3´ to amplify the downstream enhancer 
(enh2) of the cyclin D1 gene; and forward 5´-GCTCTTTACGCTCGCTAACC-3´ and 
reverse 5´-GGGCAGATCTCGACTAGGAA-3´ to amplify the upstream ER binding 
region (enh1) of this gene (Eeckhoute et al., 2006) 
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FIGURE LEGENDS 
 
Figure 1. PRL induces ERE-dependent transactivation. A) Luciferase activity 
determined in T47D cells transfected with a reporter plasmid containing 3 copies of a 
consensus ERE and incubated with PRL for the indicated time periods. Data are shown 
as the mean ± S.D of values obtained in the corresponding untreated cells at each point. 
B) Reporter activity in cells treated with PRL or E2 in the presence and absence of the 
ER antagonist ICI. Data are expressed relative to the values obtained in the 
corresponding control cells. 
 
Figure 2. PRL induces transcription of the ER target gene pS2. A) pS2 mRNA levels 
were measured by quantitative real-time PCR in cells preincubated with ICI for 1 h and 
then incubated for 24 h with PRL. Data are expressed relative to the values obtained in 
control untreated cells. B) ER mRNA levels determined in the same samples. 
 
Figure 3. PRL induces Ser-118 ER phosphorylation. A) Levels of ER 
phosphorylated in Ser-118 (P-ER and total ER levels were determined by western 
blot in T47D cells incubated with PRL for increasing time periods or with E2 for 30 
minutes. B) P-ER and ER levels determined in MCF-7 cells incubated with PRL for 
various time periods. C) T47D cells were preincubated with ICI for 2 h and then 
stimulated with PRL for kinetic analysis. In D) cells were preincubated with tamoxifen 
and then treated with PRL. E) P-ER and ER in cells preincubated for 2 
h with the inhibitors PD184352 (1 µM), LY29402 (10 µM) or PP2 (1 µM) and then 
stimulated with PRL for the times indicated. In panels A and B detection of ER by 
Western blot was carried out with an antibody, which detects a doublet where the 
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specific band is labelled with an asterisk. In panel D, the anti- ER used detects a single 
band. 
 
Figure 4. PRL induces recruitment of P-ER and ERto ERE-containing promoters. 
Binding of ER and P-Ser118-ER to the pS2 and GREB1C promoter fragments 
containing the ERE, and to an irrelevant fragment of the pS2 gene. Binding was 
determined by ChIP assays in T47D cells at different time points after E2 and PRL 
treatment. The upper panels show the inputs for each ChIP and the lower panels the 
results obtained with the ER and P-ER antibodies and with normal IgG used as a 
negative control. 
 
Figure 5. Histone H3 acetylation and coactivator recruitment at the pS2 promoter. 
Binding of ER, the p160 coactivator SRC-1 and acetylated histone H3 (H3-Ac) to the 
proximal pS2 promoter and to an irrelevant region was determined by ChIP assay after 
treatment of T47D cells with E2 and PRL as indicated. Normal IgG was used as a 
negative control. 
 
Figure 6. ER is required for PRL-dependent T47D cell proliferation. A) 
[
3
H]thymidine incorporation determined in cells treated for 72 h with PRL in the 
presence of increasing concentrations of ICI. Results are expressed relative to those 
obtained in the untreated cells. B) Cell number was counted in cells treated with PRL 
and E2 in the absence and presence of ICI. C) Flow cytometry analysis of cells treated 
with PRL and/or ICI. The left panel represents the percentage of cells in G0/G1 and the 
right panel the percentage of cells in S-phase. D) Cells transfected with a control siRNA 
or a siRNA targetting ER. After 24 h cells were shifted to serum- and phenol red-free 
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medim and ER levels were determined 48 h later. E) Cell cycle analysis in cells 
transfected with control or ER siRNAs and treated with E2 or PRL for the last 24 h. 
Figure 7. Role of ER in PRL signalling in T47D cells. A) Kinetics of ERK and AKT 
phosphorylation was determined by western blot in T47D cells pre-treated with ICI for 
2 h and then with PRL for the indicated time periods. Total levels of ERK and AKT 
were used as loading controls. B) ERK and AKT phosphorylation as well as ERlevels
were determined in cells transfected with siControl or siER and incubated with PRL 
for 30 min. ERk2 was used as a loading control. C) c-Myc, Cyclin D1 and ER levels 
in cells stimulated with PRL for the indicated time periods. ICI was added 2 h prior to 
PRL. Tubulin was used as a loading control. The specific ER band is labelled with an 
asterisk. 
 
Figure 8. PRL induces recruitment of P-ER and ERto the cyclin D1 gene sites 
responsible for E2 induction. Association of ER and P-Ser118-ER to an enhancer 
located downstream the cyclin D1 coding region (enh2), and to an upstream enhancer 
located at -2000 (enh1). Binding was determined by ChIP assays in T47D cells (panel 
A) and MCF-7 cells (panel B) at the indicated time points of incubation with E2 and 
PRL. The upper panels show the inputs for each ChIP and the lower panels the results 
obtained with the ER and P-ER antibodies and with normal IgG used as a negative 
control. 
